Vaniprevir

From Food & Medicine Encyclopedia

Vaniprevir


Vaniprevir is a protease inhibitor used in the treatment of Hepatitis C. It is a second-generation protease inhibitor developed by Merck & Co., and is specifically designed to target the NS3/4A serine protease of the Hepatitis C virus.

Mechanism of Action[edit]

Vaniprevir works by inhibiting the NS3/4A serine protease, an enzyme that the Hepatitis C virus requires for replication. By blocking this enzyme, Vaniprevir prevents the virus from replicating within the host's liver cells.

Clinical Trials[edit]

Vaniprevir has undergone Phase II and Phase III clinical trials for the treatment of Hepatitis C. In these trials, it has shown significant efficacy in reducing viral load, particularly in patients with genotype 1 Hepatitis C, which is the most common form of the virus in the United States and Europe.

Side Effects[edit]

Common side effects of Vaniprevir include fatigue, headache, nausea, and diarrhea. In rare cases, it can cause severe skin reactions and liver damage.

Regulatory Status[edit]

As of 2021, Vaniprevir is approved for use in Japan, but not in the United States or Europe. In Japan, it is marketed under the brand name MK-7009.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!







Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.